• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 91 units of Ordinary Shares, decreasing direct ownership by 0.27% to 33,251 units (SEC Form 4)

    10/2/24 4:37:12 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Zangerle John Adam

    (Last) (First) (Middle)
    70 SIR JOHN ROGERSON'S QUAY

    (Street)
    DUBLIN 2 L2 D02 R296

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    STERIS plc [ STE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Sr. VP, Gen Counsel, and Sec.
    3. Date of Earliest Transaction (Month/Day/Year)
    10/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 10/01/2024 F 91(1) D $235.78 33,251(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. 91 shares were withheld from the 202 restricted shares that vested on October 1, 2024. These 91 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 202 ordinary shares were awarded to Mr. Zangerle on October 1, 2021. These vested shares were valued at the NYSE closing market price on October 1, 2024.
    2. As of October 1, 2024, 9,155 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,157 on June 2, 2025; 819 on June 2, 2025; 846 on June 2, 2025; 1,376 on June 4, 2025; 202 on October 1, 2025; 1,157 on June 1, 2026; 846 on June 2, 2026; 1,376 on June 4, 2026 and 1,376 on June 4, 2027.
    Remarks:
    /s/ John P. Ubbing, Authorized Representative under Power of Attorney 10/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    4/7/2022$275.00Outperform
    Wolfe Research
    2/14/2022$250.00 → $270.00Market Outperform
    JMP Securities
    More analyst ratings

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/13/24 5:14:05 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:49:03 AM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:32:52 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $STE
    Leadership Updates

    Live Leadership Updates

    See more

    $STE
    SEC Filings

    See more

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $STE
    Financials

    Live finance-specific insights

    See more
    • Steris upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

      10/24/24 6:28:31 AM ET
      $STE
      Industrial Specialties
      Health Care
    • KeyBanc Capital Markets resumed coverage on Steris with a new price target

      KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00

      2/6/24 6:38:21 AM ET
      $STE
      Industrial Specialties
      Health Care
    • Morgan Stanley initiated coverage on Steris with a new price target

      Morgan Stanley initiated coverage of Steris with a rating of Equal-Weight and set a new price target of $206.00

      5/30/23 7:41:11 AM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • STERIS Announces Changes to Board of Directors

      David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

      5/11/21 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by STERIS plc (Ireland)

      144 - STERIS plc (0001757898) (Subject)

      5/20/25 4:10:47 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - STERIS plc (0001757898) (Filer)

      5/14/25 4:34:06 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by STERIS plc (Ireland)

      8-K - STERIS plc (0001757898) (Filer)

      3/3/25 5:03:38 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SVP and President, Healthcare Majors Cary L exercised 12,828 units of Ordinary Shares at a strike of $147.05 and sold $3,208,026 worth of Ordinary Shares (12,828 units at $250.08) (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      5/22/25 4:31:17 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SVP and President, Healthcare Majors Cary L sold $365,532 worth of Ordinary Shares (1,682 units at $217.32), decreasing direct ownership by 13% to 11,372 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      11/27/24 4:30:15 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 91 units of Ordinary Shares, decreasing direct ownership by 0.27% to 33,251 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      10/2/24 4:37:12 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care